{"entity":{"id":"nct07106892","kind":"trial","name":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of HLX43 Dose 1; in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.","summary":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07106892 by Shanghai Henlius Biotech, with 60 participants planned, started 2025-09-15 and due to reach its primary completion in 2026-12-30. Interventions recorded: HLX43 Dose 1;, HLX43 Dose 2; and HLX43 Dose 3;.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07106892","url":"https://clinicaltrials.gov/study/NCT07106892"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07106892","phase":"2","setting":"Phase II, Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","sponsor":"Shanghai Henlius Biotech","enrolled":60,"outcomes":[]},"route":"/trials/nct07106892/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}